SIGA Share Price

Open 2.96 Change Price %
High 2.96 1 Day -0.10 -3.27
Low 2.91 1 Week -0.15 -4.82
Close 2.96 1 Month -0.33 -10.03
Volume 11900 1 Year 0.91 44.39
52 Week High 3.40
52 Week Low 0.60
SIGA Important Levels
Resistance 2 3.01
Resistance 1 2.99
Pivot 2.94
Support 1 2.93
Support 2 2.91
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

SIGA Technologies Inc. (NASDAQ: SIGA)

SIGA Technical Analysis 2
As on 24th Mar 2017 SIGA Share Price closed @ 2.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.28 & Sell for SHORT-TERM with Stoploss of 3.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
SIGA Target for March
1st Target up-side 3.62
2nd Target up-side 3.85
3rd Target up-side 4.08
1st Target down-side 2.96
2nd Target down-side 2.73
3rd Target down-side 2.5
SIGA Other Details
Segment EQ
Market Capital 152333136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.siga.com
SIGA Address
SIGA
660 Madison Avenue
Suite 1700
New York, NY 10065
United States
Phone: 212-672-9100
Fax: 212-697-3130
SIGA Latest News
Interactive Technical Analysis Chart SIGA Technologies Inc. ( SIGA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SIGA Technologies Inc.
SIGA Business Profile
SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.